Novartis has raised its earnings expectations for 2025, following an impressive first-quarter performance fueled by significant sales growth of its key drugs. The pharmaceutical giant now anticipates a 'low double-digit' percentage increase in operating income for 2025, an upgrade from the earlier forecast of 'high single to low double-digit' growth, as reported by Reuters.
In the first quarter, Novartis saw substantial sales growth from key products, driving the company's strong performance. Kisqali's sales jumped by 43% year-over-year, Kesimpta's by 28%, and Leqvio's by a remarkable 119%. Additionally, Novartis recorded a 22% increase in operating income for 2024. The company also proposed a dividend increase to CHF 3.50 per share for 2024, marking a 6.1% rise.
Despite looming patent expirations, including that of Entresto, Novartis CEO Vas Narasimhan remains confident, expressing belief in maintaining average annual sales growth of at least 5% through 2028. This optimism stems from a robust pipeline of new drug offerings and innovation, ensuring the company remains a formidable player in the pharmaceutical market.